SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
A probabilistic model for analyzing viral risks of plasma‐derived medicinal products
6 references·1 citing·26 second hop
A probabilistic model for analyzing viral risks of plasma‐derived medicinal products (2007)A probabilistic model for analyzing viral…A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors (2005)A new strategy for estimating…Validation of the NucliSens Extractor combined with the AmpliScreen HIV version 1.5 and HCV version 2.0 test for application in NAT minipool screening (2002)Validation of the NucliSens E…Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window‐phase donations not detected by NAT (2002)Mathematic modeling of the ri…International application of the Incidence Rate/Window Period model (2002)International application of …The risks of transfusion-transmitted infection: direct estimation and mathematical modelling (2000)The risks of transfusion-tran…The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection (1997)The incidence/window period m…Remuneration of blood donors: new proof of the pudding? (2008)Remuneration of blood donors:…The Risk of Transfusion-Transmitted Viral Infections (1996)Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting (1999)Nucleic acid amplification testing of blood donors fortransfusion‐transmitted infectious diseases (2000)Estimated Risk of Transmission of the Human Immunodeficiency Virus by Screened Blood in the United States (1995)Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor population (2002)Effect of a National Disaster on Blood Supply and Safety (2003)Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000. (2003)Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States (2004)The Risk of Transfusion-Transmitted Infection (1992)Trends in Incidence and Prevalence of Major Transfusion-Transmissible Viral Infections in US Blood Donors, 1991 to 1996 (2000)Health and economic impact of posttransfusion hepatitis B and cost‐effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union (2003)Transfusion risks of yesterday and of today (2003)Residual infectious disease risk in screened blood transfusion from a high‐prevalence population: Santa Catarina, Brazil (2007)Transmission of Human Immunodeficiency Virus (HIV) by Blood Transfusions Screened as Negative for HIV Antibody (1988)Exposure of Patients to Human Immunodeficiency Virus through the Transfusion of Blood Components That Test Antibody-Negative (1989)Evaluation of Screened Blood Donations for Human Immunodeficiency Virus Type 1 Infection by Culture and DNA Amplification of Pooled Cells (1991)Current incidence and estimated residual risk of transfusion‐transmitted infections in donations made to Canadian Blood Services (2007)Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid–Amplification Testing (2004)Transfusion-transmitted infections (2007)Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing (2010)Prevention of transfusion-transmitted infections (2019)Embedded Altruism: Blood Collection Regimes and the European Union's Donor Population (2000)Paying for blood donations: still a risk? (2002)Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing (2005)Assessing the impact of HBV NAT on window period reduction and residual risk (2006)Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6‐year survey (2008)
this work references cited by second hop

References

  • 2005A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors426 cited
  • 1997The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection168 cited
  • 2002International application of the Incidence Rate/Window Period model150 cited
  • 2002Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window‐phase donations not detected by NAT117 cited
  • 2000The risks of transfusion-transmitted infection: direct estimation and mathematical modelling63 cited
  • 2002Validation of the NucliSens Extractor combined with the AmpliScreen HIV version 1.5 and HCV version 2.0 test for application in NAT minipool screening19 cited

Cited by

  • 2008Remuneration of blood donors: new proof of the pudding?9 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work